Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Hacke, W; Kaste, M; Bluhmki, E; Brozman, M; Dávalos, A; Guidetti, D; Larrue, V; Lees, KR; Medeghri, Z; Machnig, T; Schneider, D; von Kummer, R; Wahlgren, N; Toni, D; ECASS Investigators.
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
N Engl J Med. 2008; 359(13): 1317-1329.
Doi: 10.1056/NEJMoa0804656
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Members Med Uni Graz:
- Niederkorn Kurt
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke. METHODS: After exclusion of patients with a brain hemorrhage or major infarction, as detected on a computed tomographic scan, we randomly assigned patients with acute ischemic stroke in a 1:1 double-blind fashion to receive treatment with intravenous alteplase (0.9 mg per kilogram of body weight) or placebo. The primary end point was disability at 90 days, dichotomized as a favorable outcome (a score of 0 or 1 on the modified Rankin scale, which has a range of 0 to 6, with 0 indicating no symptoms at all and 6 indicating death) or an unfavorable outcome (a score of 2 to 6 on the modified Rankin scale). The secondary end point was a global outcome analysis of four neurologic and disability scores combined. Safety end points included death, symptomatic intracranial hemorrhage, and other serious adverse events. RESULTS: We enrolled a total of 821 patients in the study and randomly assigned 418 to the alteplase group and 403 to the placebo group. The median time for the administration of alteplase was 3 hours 59 minutes. More patients had a favorable outcome with alteplase than with placebo (52.4% vs. 45.2%; odds ratio, 1.34; 95% confidence interval [CI], 1.02 to 1.76; P=0.04). In the global analysis, the outcome was also improved with alteplase as compared with placebo (odds ratio, 1.28; 95% CI, 1.00 to 1.65; P<0.05). The incidence of intracranial hemorrhage was higher with alteplase than with placebo (for any intracranial hemorrhage, 27.0% vs. 17.6%; P=0.001; for symptomatic intracranial hemorrhage, 2.4% vs. 0.2%; P=0.008). Mortality did not differ significantly between the alteplase and placebo groups (7.7% and 8.4%, respectively; P=0.68). There was no significant difference in the rate of other serious adverse events. CONCLUSIONS: As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke; alteplase was more frequently associated with symptomatic intracranial hemorrhage. (ClinicalTrials.gov number, NCT00153036.)
- Find related publications in this database (using NLM MeSH Indexing)
- Acute Disease -
- Adult -
- Aged -
- Brain Ischemia - drug therapy
- Double-Blind Method - drug therapy
- Drug Administration Schedule - drug therapy
- Female - drug therapy
- Fibrinolytic Agents - administration and dosage
- Humans - administration and dosage
- Infusions, Intravenous - administration and dosage
- Intracranial Hemorrhages - chemically induced
- Logistic Models - chemically induced
- Male - chemically induced
- Middle Aged - chemically induced
- Odds Ratio - chemically induced
- Stroke - complications
- Time Factors - complications
- Tissue Plasminogen Activator - administration and dosage
- Treatment Outcome - administration and dosage